logo

AVXL

Anavex Life Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

AVXL fundamentals

Anavex Life Sciences (AVXL) released its earnings on Nov 25, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.11 (YoY +21.43%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.11
+21.43%
Report date
Nov 25, 2025
AVXL Earnings Call Summary for Q4,2025
  • Regulatory Reexamination: CHMP negative opinion expected, but Anavex to present 144-week cognitive benefit data (17.8 months saved) and Collagen 24A1 biomarker targeting 71% responsive patients.
  • Financial Strength: $120M+ cash runway, reduced clinical trial costs.
  • Breakthrough Biomarker: Collagen 24A1 mutation predicts blarcamesine response, 71% patient benefit.
EPS
Revenue

Revenue & Expenses

Key Indicators

Anavex Life Sciences (AVXL) key financial stats and ratios, covering profitability, financial health, and leverage.
Anavex Life Sciences (AVXL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Anavex Life Sciences (AVXL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Anavex Life Sciences (AVXL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Anavex Life Sciences (AVXL) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Anavex Life Sciences (AVXL) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield